Skip to main content
TipRanks
Go Ultimate75% OFF

Alligator Bioscience AB (ATORX) AI Stock Analysis

4 Followers
SE:ATORX

Alligator Bioscience AB

(Nasdaq OMX AB:ATORX)

Select Model
Rating:39Underperform
Price Target:SEK 0.01â–¼(-10.00% Downside)
Action:reiterated
Date:11/05/26

Alligator Bioscience scores near the bottom of the range. The dominant factor is its financial profile: effectively no revenue, losses at every level, a near-exhausted equity base, debt that exceeds equity, and annual cash burn larger than total assets — leaving the company dependent on fresh capital or a partnership to continue operating. Technicals reinforce the caution, with the share trading below all major moving averages, negative MACD and weak momentum indicators. Valuation provides no cushion, as the negative P/E reflects persistent losses and there is no dividend. The modest offset is management's cost discipline, which has more than halved operating losses and cash burn since 2024 and restored equity to positive territory, but this is not enough to change a high-risk profile driven by clinical and financing outcomes.

Positive Factors
Cancer immunotherapy specializationA focused antibody-immunotherapy platform gives Alligator a defined scientific direction and the opportunity to build value across multiple development programs. Progress from research through clinical trials can create durable partnering opportunities if candidates demonstrate meaningful therapeutic potential.
Negative Factors
Deep and continuing unprofitabilityThe very small revenue base relative to the net loss shows that the company remains far from commercial breakeven. Continued development spending without meaningful product revenue leaves profitability dependent on future pipeline progress, licensing transactions, or additional financing.

Alligator Bioscience AB (ATORX) vs. iShares MSCI Sweden ETF (EWD)

-100%-50%0%50%100%SE:ATORX-94.62%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 30.69M
Dividend Yield
―
Average Volume (3M)
37.74M
Price to Earnings (P/E)
-0.0
Beta (1Y)
0.94
Revenue Growth
-99.33%
EPS Growth
64.90%
Country
Sweden
Employees
11
Sector
General
Sector Strength
55
Industry
Biotechnology

Alligator Bioscience AB Business Overview & Revenue Model

Company Description

Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its dru...

How the Company Makes Money

Alligator Bioscience primarily generates or seeks to generate revenue through: (1) out-licensing and partnering its drug candidates and underlying antibody discovery/optimization capabilities to larger pharmaceutical or biotech companies in exchange...

Alligator Bioscience AB Financial Statement Overview

Summary

Financials are very weak, even by clinical-stage biotech standards. Revenue has effectively disappeared (SEK 0.3 million TTM versus SEK 57.8 million in 2024), gross profit is negative SEK 23.4 million, operating income is negative SEK 96.9 million, and the net loss is SEK 82.1 million. The balance sheet is fragile: equity has collapsed from SEK 282.3 million in 2021 to just SEK 23.2 million after dipping into deficit in 2024, while debt of SEK 27.8 million exceeds equity for a stretched ~9x debt-to-equity position. Cash flow is the biggest concern, with TTM operating and free cash flow both at negative SEK 97.3 million — more than the entire SEK 89.4 million asset base — implying heavy reliance on new equity raises or partnering income and material dilution/going-concern risk. The one genuine positive is cost discipline: operating losses and cash burn have been cut by more than half since 2024 and equity has been restored to positive territory.

Income Statement

8Very Negative

Balance Sheet

11Very Negative

Cash Flow

7Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue283.00K514.00K57.77M58.11M35.70M12.94M
Gross Profit-38.25M-54.82M57.77M58.11M-112.03M-74.04M
EBITDA-95.92M-121.98M-165.47M-237.61M-180.99M-130.36M
Net Income-82.10M-51.35M-233.89M-248.59M-193.40M-141.74M
Balance Sheet
Total Assets89.41M110.60M104.34M118.45M169.58M333.20M
Cash, Cash Equivalents and Short-Term Investments41.25M62.20M64.31M66.12M97.31M278.15M
Total Debt27.78M43.15M43.57M16.10M24.50M9.74M
Total Liabilities66.23M103.74M234.93M106.59M80.53M50.93M
Stockholders Equity23.17M6.86M-130.59M11.86M89.05M282.27M
Cash Flow
Free Cash Flow-97.31M-157.45M-212.43M-191.74M-173.05M-127.08M
Operating Cash Flow-97.31M-155.99M-212.43M-189.28M-172.61M-127.03M
Investing Cash Flow02.21M0-2.46M-440.00K-45.00K
Financing Cash Flow113.70M152.59M211.27M161.56M-7.83M301.80M

Alligator Bioscience AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.01

Price Trends

50DMA0.02Negative
100DMA0.04Negative
200DMA0.09Negative

Market Momentum

MACD-0.00Negative
RSI31.41Neutral
STOCH10.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ATORX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 31.41 is Neutral, neither overbought nor oversold. The STOCH value of 10.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ATORX.

Alligator Bioscience AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:ATORX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 369.63M1.9363.09%―――
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:BINVSE:BINV49NeutralSEK 193.46M-0.40-128.54%―-83.67%-50.29%
SE:IMMUSE:IMMU48NeutralSEK 240.41M-2.12-19.14%――13.06%
SE:ELICSE:ELIC47NeutralSEK 164.51M-6.97-56.09%――14.10%
SE:ONCOSE:ONCO44NeutralSEK 747.11M-2.75――65.37%43.28%
SE:ATORXSE:ATORX39UnderperformSEK 30.69M-0.01-439.98%―-99.33%64.90%

* General Sector Average

Performance Comparison

-50%0%50%SE:ATORXSE:BINVSE:ONCOSE:ELICSE:IMMUSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ATORX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ATORXAlligator Bioscience AB0.01-0.19-94.97%
SE:BINVBioInvent International AB2.94-28.31-90.59%
SE:ONCOOncopeptides AB1.73-3.10-64.14%
SE:ELICElicera Therapeutics AB2.46-2.66-51.90%
SE:IMMUImmunicum AB3.79-1.51-28.49%
SE:CANTACantargia AB1.31-1.86-58.64%

Alligator Bioscience AB Corporate Events

Alligator Bioscience Appoints Nomination Committee for 2027 AGM

Nov 3, 2026

Alligator Bioscience is a biotechnology company historically focused on tumor-directed immuno-oncology. Following a strategic refocus, it is prioritizing its economic interest in HLX22, an anti-HER2 monoclonal antibody developed by Shanghai Henlius,...

Alligator Bioscience Sells Mitazalimab Rights to Biossil in Strategic Refocus on HLX22

Oct 31, 2026

Alligator Bioscience has agreed to sell all global rights and assets related to its CD40 agonist antibody mitazalimab to Biossil Inc., including patents, clinical and regulatory data, manufacturing materials, drug inventory, and all future developmen...

Alligator Bioscience Boosts Share Count After Rights Issue

Oct 30, 2026

Alligator Bioscience AB has increased its number of shares and votes following a rights issue of units approved by the board in July 2026 and confirmed by an extraordinary general meeting in August 2026. As of 30 October 2026, the company’s total num...

Alligator Bioscience Plans 1-for-1,000 Reverse Share Split and Warrant Term Adjustments

Oct 27, 2026

Alligator Bioscience AB plans to seek shareholder approval at an Extraordinary General Meeting on 27 November 2026 for a 1-for-1,000 reverse split of its ordinary shares, consolidating the total number from about 3.57 billion to roughly 3.57 million...

Alligator Bioscience Calls Extraordinary Meeting to Restructure Share Capital and Board

Oct 27, 2026

Alligator Bioscience AB has called an extraordinary general meeting for 27 November 2026 in Lund, Sweden, inviting shareholders to vote on a series of corporate actions. The meeting will address share capital restructuring measures, board composition...

Alligator Bioscience Refocuses Strategy on HLX22 and Bolsters Finances

Oct 22, 2026

Alligator Bioscience has undertaken a strategic refocus in the third quarter of 2026, discontinuing independent development of its lead asset mitazalimab and concentrating on its financial interest in HLX22, which is advancing through global Phase 3...

Alligator Bioscience to Present Q3 HER2-Focused Interim Report on 22 October

Oct 15, 2026

Alligator Bioscience will publish its interim report for the July–September 2026 period, focused on its HER2-targeting activities, on 22 October 2026 at 8:00 a.m. CEST. The company will the same day host an English-language webinar and conference cal...

Alligator Bioscience Names CFO Johan Giléus as CEO Amid Strategic Refocus on HLX22

Oct 4, 2026

Alligator Bioscience has appointed its current Chief Financial Officer, Johan Giléus, as Chief Executive Officer effective 1 January 2027, succeeding Søren Bregenholt, who will remain in the role until the end of 2026 to ensure a smooth handover. Gil...

Alligator Bioscience Restructures Fenja Loan With Directed Warrant Issue

Sep 29, 2026

Alligator Bioscience has issued 187,795,097 warrants to Fenja Capital as part of a renegotiated loan arrangement linked to its recently completed rights issue. The new 2026/2031 warrants, replacing an earlier 2025/2030 series, correspond to about 5 p...

Alligator Bioscience’s Rights Issue Heavily Reliant on Guarantees, Triggers Major Dilution

Sep 22, 2026

Alligator Bioscience has reported the final outcome of its rights issue of units, in which only about 17.1 percent of the maximum 3.14 billion units were subscribed by investors, with the remainder largely covered by guarantee commitments. Each unit...

Alligator Bioscience’s Rights Issue Undersubscribed, Underwriters Step In

Sep 21, 2026

Alligator Bioscience AB has reported the preliminary outcome of its rights issue of units, launched in July 2026, with subscriptions totaling about 17.1 percent through exercise of unit rights and 16.7 percent without rights. This level of demand mea...

Alligator Bioscience Launches SEK 125.6 Million Rights Issue to Refocus Oncology Pipeline

Aug 31, 2026

Alligator Bioscience has published a prospectus for a rights issue of up to 3,140,534,240 units, each comprising two shares and two series of warrants, at a subscription price of SEK 0.04 per unit. The offer, running from 4 to 18 September 2026, coul...

Alligator Bioscience Restructures Capital and Launches Major Rights Issue

Aug 26, 2026

Alligator Bioscience’s extraordinary general meeting approved multiple changes to its capital structure, including amendments to the Articles of Association and significant reductions of share capital to cover losses and reallocate funds to unrestric...

Alligator Bioscience exits mitazalimab development to refocus on HLX22 royalties and recapitalisation

Aug 26, 2026

Alligator Bioscience reported a weak second quarter with no significant operational events, continuing to post operating losses and declining cash, while progressing investigator-led studies and data presentations for mitazalimab and highlighting enc...

Alligator Bioscience Schedules August Earnings Call Amid Strategic Refocus

Aug 20, 2026

Alligator Bioscience will publish its interim report for the April–June 2026 period related to its HER2-targeting activities on 26 August 2026. On the same day, the company will host an earnings webinar and conference call in English, led by CEO Søre...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026